Xencor is developing a pipeline of drug candidates for cancer and other serious diseases, built on its XmAb protein engineering platform. Xencor also licenses its Fc domains to partners for therapeutic targets outside its own areas of focus. From company websiteSource · Source · checked 2026-10-19
Sources for this description (2)
Xencor is developing a pipeline of drug candidates for cancer and other serious diseases, built on its XmAb protein engineering platform.
“Powered by its XmAb ® protein engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat patients with cancer and other serious diseases.” https://xencor.com/ (2026-10-19)
Xencor also licenses its Fc domains to partners for therapeutic targets outside its own areas of focus.
“Xencor extends the use of the XmAb technology through licenses of these high-performance Fc domains to partners interested in therapeutic targets outside of Xencor’s areas of focus.” https://xencor.com/about-us/ (2026-10-19)
Trial start Phase 1: Study of XmAb412 in Healthy Participants source ↗
Trial start 1: Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors source ↗
Trial start 1: A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases source ↗
Trial start 1: A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis source ↗
Trial start Phase 1/Phase 2: Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis source ↗
Trial start 1: Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors source ↗
Trial start Phase 1/Phase 2: Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC source ↗
Trial start Phase 1: A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors source ↗
Trial start 1: Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors source ↗
Trial start Phase 1: Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis source ↗
Trial start Phase 2: A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies source ↗
Trial start Phase 1: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma source ↗
Trial start 2: Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) source ↗
Trial start Phase 2: XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer source ↗
Trial start Phase 1/Phase 2: Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer source ↗
Trial start Phase 1: Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers source ↗
Trial start Phase 1: A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors source ↗
Trial start Phase 1: A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) source ↗
Trial start Phase 1: Study Evaluating AMG 424 in Subjects With Multiple Myeloma source ↗
Trial start Phase 1: A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors source ↗
Trial start Phase 1: A Study of XmAb®18087 in Subjects With NET and GIST source ↗
Trial start Phase 1: Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies source ↗
Trial start Phase 1: Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 source ↗
Trial start Phase 1: PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies source ↗
Trial start Phase 1: XmAb5871 Bioavailability Study source ↗
Showing 25 of 30 dated events.
Upcoming milestones
2027-02 (ESTIMATED) · Phase 1 · Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma · NCT05433142
2027-05 (ESTIMATED) · Phase 1 · Study of XmAb412 in Healthy Participants · NCT07713485
2027-12 (ESTIMATED) · 1 · Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors · NCT06276491
2027-12 (ESTIMATED) · Phase 1/Phase 2 · Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis · NCT06619990
2028-06 (ESTIMATED) · 1 · A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis · NCT07230353
2028-10 (ESTIMATED) · 1 · A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases · NCT07284797
2028-12 (ESTIMATED) · 1 · Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors · NCT07593092
Estimated primary completion per ClinicalTrials.gov. Dates move.
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Phase 1
Completed
2007-12
2010-04 (actual)
NIH awards 2
Annual award amounts. Total $199K.
NIH award 1R43GM069256-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI DESJARLAIS, JOHN R; recipient as written: XENCOR, INC., MONROVIA, CA. Rational Optimization of Protein Solubility source ↗
NIH award 1R43GM066489-01 FY2002: $99,000 awarded for that fiscal year; activity R43 (SBIR); PI DOBERSTEIN, STEPHEN K; recipient as written: XENCOR, INC., MONROVIA, CA. Genome-wide Profiling of Chemical-Protein Inter source ↗
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
